Ran Nussbaum, Director at Eloxx Pharmaceuticals, Inc. (ELOX), bought 12,600 shares at $7.55 ($98K) on 2018-03-21, disclosed to the SEC on 2018-03-23.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.55 | 1,585 | $12K | 12.2% |
| 2 | $7.55 | 1,760 | $13K | 13.6% |
| 3 | $7.55 | 3,255 | $25K | 25.1% |
| 4 | $8.00 | 1,441 | $12K | 11.8% |
| 5 | $8.00 | 1,600 | $13K | 13.1% |
| 6 | $8.00 | 2,959 |
| $24K |
| 24.2% |
| Total | $7.76 avg | 12,600 | $98K | 100% |
| Filing → |
| KROS | BUY | 2020-04-13 | $7.0M | — | Filing → |
| ARQL | BUY | 2019-07-01 | $4.1M | — | Filing → |
| ELOX | BUY | 2019-06-26 | $1.8M | — | Filing → |